Richard Law
Stock Analyst at Goldman Sachs
(3.18)
# 1,080
Out of 4,981 analysts
66
Total ratings
46.88%
Success rate
15.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $37.10 | +40.16% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $18.87 | +59.02% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $52.62 | +55.83% | 4 | Aug 6, 2025 | |
| ARQT Arcutis Biotherapeutics | Initiates: Neutral | $18 | $17.29 | +4.11% | 1 | Jul 25, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $7.77 | +131.66% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $4.51 | -33.48% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.16 | +311.39% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $24.44 | +26.87% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $24.81 | +20.92% | 1 | Apr 8, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $69.53 | +4.99% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $4.81 | +128.69% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $20.60 | +128.16% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $56.26 | +11.98% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $47.00 | -21.28% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $11.42 | +565.50% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.69 | +420.45% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.74 | +688.11% | 4 | May 8, 2023 |
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $37.10
Upside: +40.16%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $18.87
Upside: +59.02%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $52.62
Upside: +55.83%
Arcutis Biotherapeutics
Jul 25, 2025
Initiates: Neutral
Price Target: $18
Current: $17.29
Upside: +4.11%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $7.77
Upside: +131.66%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $4.51
Upside: -33.48%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.16
Upside: +311.39%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $24.44
Upside: +26.87%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $24.81
Upside: +20.92%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $69.53
Upside: +4.99%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.81
Upside: +128.69%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $20.60
Upside: +128.16%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $56.26
Upside: +11.98%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $47.00
Upside: -21.28%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $11.42
Upside: +565.50%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.69
Upside: +420.45%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.74
Upside: +688.11%